Matinas BioPharma Holdings Operating Expenses Growth & History (MTNB)
Matinas BioPharma Holdings's operating expenses was $7.0M for fiscal 2025.
View full Matinas BioPharma Holdings company overviewMatinas BioPharma Holdings annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.0M | −$13.2M | −65.48% |
| 2024 | 2024-12-31 | $20.2M | −$4.7M | −18.90% |
| 2023 | 2023-12-31 | $24.9M | −$2.9M | −10.50% |
| 2022 | 2022-12-31 | $27.8M | $3.0M | +12.15% |
| 2021 | 2021-12-31 | $24.8M | $403,115 | +1.65% |
| 2020 | 2020-12-31 | $24.4M | $5.4M | +28.16% |
| 2019 | 2019-12-31 | $19.0M | $4.2M | +28.74% |
| 2018 | 2018-12-31 | $14.8M | −$1.9M | −11.32% |
| 2017 | 2017-12-31 | $16.7M | $8.4M | +101.67% |
| 2016 | 2016-12-31 | $8.3M | −$1.8M | −18.29% |
| 2015 | 2015-12-31 | $10.1M | −$359,006 | −3.43% |
| 2014 | 2014-12-31 | $10.5M | $6.8M | +181.89% |
| 2013 | 2013-12-31 | $3.7M | — | — |
Matinas BioPharma Holdings quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.6M | −$282,000 | −15.35% |
| Q1 2026 | 2026-03-31 | $1.9M | −$10,000 | −0.51% |
| Q4 2025 | 2025-12-31 | $1.6M | — | — |
| Q3 2025 | 2025-09-30 | $1.6M | — | — |
| Q2 2025 | 2025-06-30 | $1.8M | — | — |
| Q1 2025 | 2025-03-31 | $1.9M | — | — |
| Q4 2023 | 2023-12-31 | $5.9M | — | — |
| Q3 2023 | 2023-09-30 | $6.1M | −$391,000 | −5.99% |
| Q2 2023 | 2023-06-30 | $6.2M | −$829,000 | −11.86% |
| Q1 2023 | 2023-03-31 | $6.7M | — | — |
| Q3 2022 | 2022-09-30 | $6.5M | −$352,944 | −5.13% |
| Q2 2022 | 2022-06-30 | $7.0M | $2.2M | +45.90% |
| Q4 2021 | 2021-12-31 | $6.7M | — | — |
| Q3 2021 | 2021-09-30 | $6.9M | $1.2M | +20.66% |
| Q2 2021 | 2021-06-30 | $4.8M | — | — |
| Q1 2021 | 2021-03-31 | $6.4M | — | — |
| Q3 2020 | 2020-09-30 | $5.7M | $1.1M | +24.98% |
| Q3 2019 | 2019-09-30 | $4.6M | $1.6M | +54.40% |
| Q2 2019 | 2019-06-30 | $4.6M | $1.1M | +31.93% |
| Q4 2018 | 2018-12-31 | $4.2M | −$508,856 | −10.88% |
| Q3 2018 | 2018-09-30 | $3.0M | −$498,967 | −14.45% |
| Q2 2018 | 2018-06-30 | $3.5M | −$526,466 | −13.09% |
| Q1 2018 | 2018-03-31 | $4.2M | −$351,507 | −7.81% |
| Q4 2017 | 2017-12-31 | $4.7M | $2.1M | +82.33% |
| Q3 2017 | 2017-09-30 | $3.5M | $1.6M | +88.17% |
| Q2 2017 | 2017-06-30 | $4.0M | $2.4M | +148.19% |
| Q1 2017 | 2017-03-31 | $4.5M | $2.3M | +101.22% |
| Q4 2016 | 2016-12-31 | $2.6M | −$218,014 | −7.84% |
| Q3 2016 | 2016-09-30 | $1.8M | −$383,515 | −17.29% |
| Q2 2016 | 2016-06-30 | $1.6M | −$858,565 | −34.64% |
| Q1 2016 | 2016-03-31 | $2.2M | −$388,766 | −14.80% |
| Q4 2015 | 2015-12-31 | $2.8M | −$527,832 | −15.95% |
| Q3 2015 | 2015-09-30 | $2.2M | −$386,707 | −14.84% |
| Q2 2015 | 2015-06-30 | $2.5M | $58,307 | +2.41% |
| Q1 2015 | 2015-03-31 | $2.6M | $497,226 | +23.35% |
| Q4 2014 | 2014-12-31 | $3.3M | $1.5M | +83.50% |
| Q3 2014 | 2014-09-30 | $2.6M | $1.2M | +79.30% |
| Q2 2014 | 2014-06-30 | $2.4M | $2.1M | +604.92% |
| Q1 2014 | 2014-03-31 | $2.1M | $2.0M | +1798.66% |
| Q4 2013 | 2013-12-31 | $1.8M | — | — |
| Q3 2013 | 2013-09-30 | $1.5M | — | — |
| Q2 2013 | 2013-06-30 | $343,371 | — | — |
| Q1 2013 | 2013-03-31 | $112,133 | — | — |
Matinas BioPharma Holdings operating expenses trends
Over the last five fiscal years, Matinas BioPharma Holdings's operating expenses decreased from $24.4M to $7.0M, a change of −$17.4M. The latest reported quarter, Q2 2026, shows $1.6M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Matinas BioPharma Holdings source filings ↗